Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Clinical trial NCT06915753 · RECRUITING

Trial details

NCT number: NCT06915753
Sponsor: Tyra Biosciences, Inc
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Hepatocellular Carcinoma Solid Tumors Solid Tumor, Adult FGFR Gene Amplification FGFR Gene Alterations FGFR3 Gene Alteration FGFR3 Gene Mutation Advanced Solid Tumors FGFR4 Gene Mutation FGFR4 Gene Fusions FGF19 Gene Amplification FGF19 Gene Overexpression

Start date: 2025-04-24
Primary completion: 2028-01-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.